We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Dynavax Technologies will soon resume a Phase III study of its hepatitis B vaccine Heplisav because the FDA lifted an 18-month clinical hold on testing it in patients with chronic kidney disease.